Cell Therapy Medical Safety &
Pharmacovigilance

Cell therapy products carry a distinct safety profile. Cytokine release syndrome, ICANS, prolonged cytopenias, and on-target off-tumor
Toxicities demand dedicated medical safety oversight that understands the biology, not just the regulatory forms.
DES Pharma serves as a trusted extension of your team across clinical and commercial safety operations.

Because Cell Therapy Patient Safety Requires Focused OversightCell Therapy Medical Safety
and Pharmacovigilance

CAR-T-associated CRS can escalate from grade 1 to grade 4 within hours. ICANS requires
neurologist-graded assessment. Long-term insertional oncogenesis risk demands 15-year follow-up programs. These are not analogous to conventional biologic adverse events, and they require medical safety professionals who understand the biology behind the risk. When in-house capacity is limited, DES Pharma provides the leadership, scale, and clinical judgment needed to move cell therapy programs forward with confidence.

Phase 1/2:

Proactive signal detection, CRS and ICANS risk characterization, risk mitigation strategy, and safety communication for early-stage cell therapy programs, with specific attention to cell therapy-specific toxicities and CBER/OTAT IND safety requirements.

Phase 3/Post-Authorization

Comprehensive Phase 3 and post-approval safety oversight for cell therapy programs: de-risking development, satisfying CBER/OTAT regulatory expectations, and protecting patients across the product lifecycle, including long-term follow-up obligations.

Pharmacovigilance

Global, inspection-ready pharmacovigilance systems for cell therapy products, combining compliant case management, blinded oversight, strong governance, and rapid regulatory response to de-risk development and support lifecycle safety obligations.

Our medical safety and pharmacovigilance teams combine strategic insight with hands-on execution to deliver safety solutions that support confident clinical decision-making, regulatory success,
and sustainable cell therapy program growth. We see the patient behind every batch record,
and that drives everything we build.

Get Started Advance Your Cell Therapy
Program with Confidence

Start building reliable, inspection-ready medical safety and
pharmacovigilance systems for your cell therapy program today.